James A. C. Bertlin

James A. C. Bertlin

Auto-generated profile, based on publicly available information

James A. C. Bertlin

University of Cambridge 1 Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Department of Medicine Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JBJames A C Bertlin
James A C Bertlin
TPTekle Pauzaite
Tekle Pauzaite
QLQian Liang
Qian Liang
NWNiek Wit
Niek Wit
JWJames C Williamson
James C Williamson
JNJames Alexander Nathan
James Alexander Nathan
Summary: Clear cell renal cell carcinoma (ccRCC) represents the most common form of kidney cancer and is typified by biallelic inactivation of the von Hippel-Lindau ( VHL ) tumour suppressor gene. Here, we undertake genome-wide CRISPR/Cas9 screening to reveal synthetic lethal interactors of VHL , and uncover that loss of Core Binding Factor β (CBF-β) causes cell death in VHL -null ccRCC cell lines and impairs tumour establishment and growth in vivo . This synthetic relationship is independent of the elevated activity of hypoxia inducible factors (HIFs) in VHL -null cells, but does involve the RUNX transcription factors that are known binding partners of CBF-β. Mechanistically, CBF-β loss leads to upregulation of type I interferon signalling, and we uncover a direct inhibitory role for CBF-β at the STING locus controlling Interferon Stimulated Gene expression. Targeting CBF-β in kidney cancer both selectively induces tumour cell lethality and promotes activation of type I interferon signalling.

12 March 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
JBJames A. C. Bertlin
James A. C. Bertlin
TPTekle Pauzaite
Tekle Pauzaite
QLQian Liang
Qian Liang
NWNiek Wit
Niek Wit
JWJames C. Williamson
James C. Williamson
JNJames Alexander Nathan
James Alexander Nathan
Clear cell renal cell carcinoma (ccRCC) represents the most common form of kidney cancer and is typified by biallelic inactivation of the von Hippel-Lindau ( VHL ) tumour suppressor gene. Here, we undertake genome-wide CRISPR/Cas9 screening to reveal synthetic lethal interactors of VHL , and uncover that loss of Core Binding Factor β (CBF-β) causes cell death in VHL -null ccRCC cell lines and impairs tumour establishment and growth in vivo. This synthetic relationship is independent of the elevated activity of hypoxia inducible factors (HIFs) in VHL -null cells, but does involve the RUNX transcription factors that are known binding partners of CBF-β. Mechanistically, CBF-β loss leads to upregulation of type I interferon signalling, and we uncover a direct inhibitory role for CBF-β at the STING locus controlling Interferon Stimulated Gene expression. Targeting CBF-β in kidney cancer both selectively induces tumour cell lethality and promotes activation of type I interferon signalling.

19 May 2026 in Cancer Research
Verified
Journal Article
Open access
PDF file
BOBrian M. Ortmann
Brian M. Ortmann
TPTekle Pauzaite
Tekle Pauzaite
JBJames A.C. Bertlin
James A.C. Bertlin
RSRachel V. Seear
Rachel V. Seear
EAEsther Arnaiz
Esther Arnaiz
JNJames Alexander Nathan
James Alexander Nathan
The cellular response to hypoxia is driven by hypoxia-inducible factors (HIF), which regulate genes involved in glycolysis, angiogenesis, and cell proliferation, as well as inflammation and tumor progression. HIF activation is well characterized and is primarily regulated by oxygen-dependent prolyl hydroxylation and subsequent degradation. SET1B, a histone H3 lysine 4 methyltransferase, has recently emerged as a key modulator of HIF target gene transcription, but evidence suggests that it plays a broader role in modulating HIF transcriptional activity beyond histone methylation. In this study, we revealed that SET1B interacts with RNA polymerase II to coordinate sustained HIF-mediated transcriptional activity through multiple functional domains. In clear-cell renal cell carcinoma (ccRCC), SET1B is critical for sustained HIF activity, and SET1B expression correlated with disease progression and metastasis in patient samples. Moreover, SET1B depletion enhanced the efficacy of HIF2 inhibitors. These findings establish SET1B as a driver of tumor progression and potential therapeutic target in ccRCC. Significance: SET1B functions as a key regulator of HIF-dependent transcription and cancer growth under low-oxygen conditions, revealing a therapeutic target to enhance treatment efficacy and potentially slow disease progression in kidney cancer.

4 August 2026
Verified
Other
Open access
PDF file
BOBrian M. Ortmann
Brian M. Ortmann
TPTekle Pauzaite
Tekle Pauzaite
JBJames A.C. Bertlin
James A.C. Bertlin
RSRachel V. Seear
Rachel V. Seear
EAEsther Arnaiz
Esther Arnaiz
JNJames Alexander Nathan
James Alexander Nathan
SET1B interacts with the RNA Pol II complex and requires multiple functional domains to coordinate HIF activity.

4 August 2026
Verified
Other
Open access
BOBrian M. Ortmann
Brian M. Ortmann
TPTekle Pauzaite
Tekle Pauzaite
JBJames A.C. Bertlin
James A.C. Bertlin
RSRachel V. Seear
Rachel V. Seear
EAEsther Arnaiz
Esther Arnaiz
JNJames Alexander Nathan
James Alexander Nathan
Model for the role of SET1B in ccRCC. In ccRCC, HIF2 is constitutively active because of the loss of VHL protein. SET1B is recruited to HIF target genes by the HIF complex, in which it plays a critical role in initiating and sustaining HIF transcription. This is achieved through its H3K4me3 activity and its interaction with the RNA Pol II complex. The enhanced HIF2 transcription leads to increased angiogenesis, metastasis, and disease progression.

4 August 2026
Verified
Other
Open access
PDF file
BOBrian M. Ortmann
Brian M. Ortmann
TPTekle Pauzaite
Tekle Pauzaite
JBJames A.C. Bertlin
James A.C. Bertlin
RSRachel V. Seear
Rachel V. Seear
EAEsther Arnaiz
Esther Arnaiz
JNJames Alexander Nathan
James Alexander Nathan
SET1B is required for sustained HIF-2 activity.